WieslanderA.P., NordinM.K., KjellstrandP.T.T., BobergU.C.Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929.Kidney Int1991; 40: 77–9.
2.
WieslanderA.P., NordinM.K., MartinsonE., KjellstrandP.T.T., BobergU.C.Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol1993; 39: 343–8.
3.
WieslanderA.Cytotoxicity of glucose degradation products in PD-fluids. In: Nephrology.Lund, Sweden: University of Lund; 1995.
4.
Tranaeus A, for the Bicarbonate/Lactate Study Group.A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution — clinical benefits.Perit Dial Int2000; 20: 516–23.
5.
RippeB., SimonsenO., HeimburgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
6.
WilliamsJ.D., TopleyN., KraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int [in press].
7.
SommersF., FaictD., VogesM., BalteauP.Glucose degradation product (GDP) profile of a new family of peritoneal dialysis solutions: Physioneal Clear-Flex.J Am Soc Nephrol [in press].
8.
GriffinJ.C., MarieS.C.Glucose degradation in the presence of sodium lactate during autoclaving at 121°C.Am J Hosp Pharm1958; 15: 893–5.
9.
HeimlichK.R., MartinA.N.A kinetic study of glucose degradation in acid solution.J Am Pharm Assoc1960; 49: 592–7.
10.
KjellstrandP., ErixonM., WieslanderA., LindénT., MartinsonE.Temperature: The single most important factor for degradation of glucose fluids during storage.Perit Dial Int2004; 24: 385–91.
11.
ErixonM., LindénT., KjellstrandP., CarlssonO., ErnebrantM., ForsbäckG.PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization.Perit Dial Int2004; 24: 392–8.
12.
HendersonI.S.Composition of peritoneal dialysis solutions: Potential hazards.Blood Purif1989; 7: 86–94.
13.
WitowskiJ., KorybalskaK., WisniewskaJ., BreborowiczA., GahlG.M., FreiU.Effect of glucose degradation products on human peritoneal mesothelial cell function [In process citation].J Am Soc Nephrol2000; 11: 729–39.
14.
WitowskiJ., WisniewskaJ., KorybalskaK., BenderT.O., BreborowiczA., GahlG.M.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
15.
InagiR., MiyataT., YamamotoT., SuzukiD., UrakamiK., SaitoA.Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463: 260–4.
LindenT., CohenA., DeppischR., KjellstrandP., WieslanderA.3,4-Dideoxyglucosone-3-ene (3,4-DGE): A cytotoxic glucose degradation product in fluids for peritoneal dialysis.Kidney Int2002; 62: 697–703.
18.
NakayamaM., KawaguchiY., YamadaK., HasegawaT., TakazoeK., KatohN.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int1997; 51: 182–6.
19.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
20.
NiwaT.3-Deoxyglucosone: Metabolism, analysis, biological activity, and clinical implication.J Chromatogr B Biomed Sci Appl1999; 731: 23–36.
21.
NiwaH., TakedaA., WakaiM., MiyataT., YasudaY., MitsumaT.Accelerated formation of N epsilon-(carboxymethyl) lysine, an advanced glycation end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons.Biochem Biophys Res Commun1998; 248: 93–7.
22.
ThornalleyP.J., LangborgA., MinhasH.S.Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose.Biochem J1999; 344(Pt 1): 109–16.
23.
LindenT., ForsbackG., DeppischR., HenleT., WieslanderA.3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis.Perit Dial Int1998; 18: 290–3.
24.
KatoF., MizukoshiS., AoyamaY., MatsuokaH., TanakaH., NakamuraK.Immunosuppressive effects of 3,4-dideoxyglucosone-3-ene, an intermediate in the Maillard reaction.J Agric Food Chem1994; 42: 2068–73.
25.
LindenT., ForsbäckG., DeppischR., HenleT., WieslanderA.3-Deoxyglucosone in fluids for peritoneal dialysis [Abstract].J Am Soc Nephrol1997; 8: 267.
26.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
27.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
28.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
29.
MortierS., De VrieseA.S., McLoughlinR.M., TopleyN., SchaubT.P., Passlick-DeetjenJ.Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane.J Am Soc Nephrol2003; 14: 1296–306.
30.
MortierS., De VrieseA.S., Van de VoordeJ., SchaubT.P., Passlick-DeetjenJ., LameireN.H.Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration, and glucose degradation products.J Am Soc Nephrol2002; 13: 480–9.
